Logo

Takeda Signs an Exclusive License Agreement with Poseida for Novel Non-Viral In Vivo Gene Therapies

Share this
Takeda Signs an Exclusive License Agreement with Poseida for Novel Non-Viral In Vivo Gene Therapies

Takeda Signs an Exclusive License Agreement with Poseida for Novel Non-Viral In Vivo Gene Therapies

Shots:

  • The parties will initially develop up to 6 in vivo gene therapy programs utilizing Poseida's piggyBac- Cas-CLOVER & biodegradable nanoparticle technology for 6 liver & HSC directed indications. Takeda has an option to add 2 additional programs and is obligated to provide funding for all program's R&D costs
  • Poseida to receive $45M up front & preclinical milestones exceeding $125M- if milestones for 6 programs are achieved. The company is also eligible for ~2.7B milestones for all 6 programs and ~$3.6B if the milestones related to the 2 optional programs are also achieved
  • Poseida will lead research activities up to candidate selection- after which Takeda will lead development & commercialization

  | Ref: PR Newswire | Image: Poseida

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions